The Power of Communication

Cheryl ProvalTalk is cheap these days, with no shortage of pundits on the TV, the radio, and the Internet offering their opinions, platitudes, and points of view. Communication, on the other hand, is not so prevalent. In fact, I would observe that our society appears to have reached the nadir of its ability to explain, listen, and interact. As a health care leader, your ability to communicate is an essential and powerful asset, but with all of the noise and talk out there, it is not enough to simply communicate any longer. You must over-communicate, believes Dolan Dalpoas, FACHE, CEO of Abraham Lincoln Memorial Hospital. As the CEO of a rural hospital that merged with a larger entity, Dalpoas shares his experience in this issue of Health CXO. We also hear from the CEO of one of health care’s more unique success stories, Scott & White, on team building and leadership, and listen in on the strategy of a California nonprofit insurer that is preparing to enroll and serve as many as 300,000 new low-income patients in 2014. Let me know if you are finding the articles in Health CXO, emailed to you six times a year, useful: Let's communicate. Cheryl Proval | cproval@imagingbiz.com
Cheryl Proval,

Vice President, Executive Editor, Radiology Business

Cheryl began her career in journalism when Wite-Out was a relatively new technology. During the past 16 years, she has covered radiology and followed developments in healthcare policy. She holds a BA in History from the University of Delaware and likes nothing better than a good story, well told.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.